The Effects of a Multi-ingredient Night-time Tea on Sleep Quality, Wellbeing and Markers of Immune Function

Sleep Clinical Trial

Official title:

The Effects of a Multi-ingredient Night-time Tea on Sleep Quality, Wellbeing and Markers of Immune Function: a Randomised, Controlled, Crossover Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05478980
• Other study ID #: 50CE1
• Status: Completed
• Phase: N/A
• Start date: November 3, 2021
• Est. completion date: August 17, 2022

Study information

• Verified date: October 2021
• Source: Northumbria University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of the study is to determine whether a night-time tea can improve subjective sleep quality in healthy sleepers and self-reported poor sleepers, compared to a control drink.

Description:

The study will adopt a randomised, double-blind, placebo controlled, crossover design. Sixty-eight healthy adults aged 18+ (34 good sleepers and 34 poor sleepers) will be recruited from the general population. Good sleepers will be recruited if they have a stable sleep-wake schedule (i.e. bed/wake time within the range of 22.00 - 09.00 and with at least 6.5 hours of sleep duration reported per night). Poor sleepers will be recruited if they report subjective sleep difficulties (i.e. poor sleep quality or unrefreshing sleep) and if they display a Pittsburgh Sleep Quality Index total score of >5. Participants will consume both an active tea, and a control tea in a counterbalanced order for 7 days (separated by a 7-day washout period). Participants will complete questionnaires assessing mood, quality of life and sleep and provide blood samples to assess immunological markers. Sleep monitoring will also be conducted using actigraphy sleep monitoring and sleep diaries. Assessments will be made at baseline and following 7 days supplementation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 78
• Est. completion date: August 17, 2022
• Est. primary completion date: August 17, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Healthy male and female adults aged 18 years and above. Both good sleepers and poor sleepers will be recruited. Good sleepers will be recruited if they have a stable sleep-wake schedule (i.e. bed/wake time within the range of 22.00 - 09.00 and with at least 6.5 hours of sleep duration reported per night). Poor sleepers will be recruited if they report subjective sleep difficulties (i.e. poor sleep quality or unrefreshing sleep) and if they display a Pittsburgh Sleep Quality Index total score of >5. Exclusion Criteria: Both good and poor sleeper participants cannot participate if they display evidence of current or previous sleep disorders (e.g. sleep apnoea, insomnia, circadian rhythm disorders); an initial screening for sleep disorders will be conducted using the Sleep Disorders Screening Checklist - 25 (SDS-CL).

• Participants must not be shift workers
• Cannot currently be participating in other research trials which will compromise the results here
• Participants cannot take part if they will be sleeping at a location other than their usual residence during participation
• Nor if they have experienced travel across multiple time zones within the last three months or will be experiencing travel across multiple time zones during the study
• Participants cannot take part if they have current or previous mood disturbances
• Are currently unwell with anything that impacts sleep
• Are currently using medication which affects the central nervous system
• Or are currently misusing alcohol or drugs

Related Conditions & MeSH terms

• Mood
• Poor Quality Sleep
• Sleep

Intervention

Dietary Supplement:
• Night Time Tea
Night-time Tea
• Control Tea
Feel New Tea

Locations

Country	Name	City	State
United Kingdom	Brain Performance Nutrition Research Centre	Newcastle Upon Tyne	Tyne & Wear

Sponsors (1)

Lead Sponsor	Collaborator
Northumbria University

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Consensus sleep diary (CSD) - Subjective sleep quality		Following 7 days of intervention
Secondary	Consensus sleep diary (CSD) - Subjective sleep continuity (Total sleep time)		Following 7 days of intervention
Secondary	Consensus sleep diary (CSD) - Subjective sleep continuity (Time in bed)		Following 7 days of intervention
Secondary	Consensus sleep diary (CSD) - Subjective sleep continuity (Sleep efficiency %)		Following 7 days of intervention
Secondary	Consensus sleep diary (CSD) - Subjective sleep continuity (Sleep latency)		Following 7 days of intervention
Secondary	Consensus sleep diary (CSD) - Subjective sleep continuity (Number of awakenings and wake after sleep onset)		Following 7 days of intervention
Secondary	Karolinska Sleepiness Scale (KSS)		Following 7 days of intervention
Secondary	Positive and negative affect schedule (PANAS)		Following 7 days of intervention
Secondary	World Health Organization Quality of Life- Brief (WHOQOL-BREF)		Following 7 days of intervention
Secondary	Short-Form Health Survey 36 (SF-36)		Following 7 days of intervention
Secondary	Actigraphy objective sleep measures (Time in bed)		Following 7 days of intervention
Secondary	Actigraphy objective sleep measures (Total sleep time)		Following 7 days of intervention
Secondary	Actigraphy objective sleep measures (Sleep efficiency %)		Following 7 days of intervention
Secondary	Actigraphy objective sleep measures (Number of awakenings)		Following 7 days of intervention
Secondary	Actigraphy objective sleep measures (Sleep latency)		Following 7 days of intervention
Secondary	Actigraphy objective sleep measures (wake after sleep onset)		Following 7 days of intervention
Secondary	Immunological markers (Interleukins-6)		Following 7 days of intervention
Secondary	Immunological markers (Interleukins-10)		Following 7 days of intervention
Secondary	Immunological markers (Tumour Necrosis Factor - alpha (TNF-a))		Following 7 days of intervention
Secondary	Immunological markers (C-Reactive protein)		Following 7 days of intervention
Secondary	Immunological markers (Cortisol)		Following 7 days of intervention